-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Oscar Health, Raises Price Target to $39

Benzinga·08/07/2026 18:46:42
Listen to the news
Barclays analyst Andrew Mok maintains Oscar Health (NYSE:OSCR) with a Overweight and raises the price target from $35 to $39.